Experimental data from ambr15 and ambr250 bioreactors are now directly captured and integrated into the Genedata Bioprocess workflow management system
October 2, 2018
Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced a new out-of-the-box integration of the Genedata Bioprocess® platform with the ambr® mini-bioreactor systems from Sartorius, a leading international pharmaceutical and laboratory equipment supplier. This enables the automatic import of raw instrument data into the Genedata Bioprocess platform, where the data can be processed and interpreted in the greater context of all data collected along the complete bioprocess development workflow. The integrations are instrument-specific, versioned, and maintained by Genedata.
ambr systems can now be easily plugged into the Genedata Bioprocess platform, which acts as a data backbone connecting all information from upstream, downstream, formulation, and analytics development units. This new integration capability leads to significant efficiency gains along the full bioprocess workflow.
Genedata Bioprocess is a first-in-class enterprise software solution that enables fully integrated workflow support for large-molecule development and CMC. As an integrated data backbone, it enables the cost-efficient development of next-generation manufacturing processes. Genedata Bioprocess is a modular system that supports the full workflow - from cell line development, upstream process development (USP), downstream process development (DSP), formulation development (FD) and analytical development (AD). The platform scales with highest data volumes and integrates all relevant experimental data, such as from bioreactors, purification instruments, or analytics devices. Genedata Bioprocess has been co-developed with major biopharmaceutical companies over the past five years.
“Our customers can now effortlessly connect Sartorius ambr systems to our Genedata Bioprocess platform. This enables a straight-forward setup of a fully integrated platform,” said Dr. Othmar Pfannes, CEO of Genedata. “The seamless integration between bioprocess instrumentation and Genedata Bioprocess simplifies day-to-day operations, saves time, and lowers our customers’ total cost of ownership. We look forward to expanding our established Ready-to-Run program to other instruments and technologies to further streamline bioprocess development operations.”